Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
40 studies found for:    Thimerosal
Show Display Options
Download search resultsDownload the search results for:
Thimerosal (40 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations
Condition: Dermatitis, Contact
Intervention: Biological: TRUE TEST Skin patch test Bioequivalence
2 Completed Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04
Condition: Influenza
Interventions: Biological: Thiomersal free trivalent influenza split vaccine 2003/2004;   Biological: GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004
3 Completed Mercury Levels in Premature and LBW Infants Receiving Thimerosal-containing Vaccines
Condition: Mercury Levels
Intervention:
4 Completed
Has Results
Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations
Condition: Influenza Infection
Interventions: Biological: Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A);   Biological: Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)
5 Completed Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults
Condition: Influenza
Interventions: Biological: CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free;   Biological: CSL Trivalent Inactivated Influenza Vaccine with Thimerosal;   Biological: Placebo with Thimerosal
6 Completed Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03
Condition: Influenza
Interventions: Biological: Thiomersal free trivalent influenza split vaccine 2002/2003;   Biological: GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003
7 Completed
Has Results
Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs
Condition: Hepatitis B
Interventions: Biological: Engerix™-B (thiomersal-free) 20µg;   Biological: 10 μg Engerix™-B (preservative-free);   Biological: placebo
8 Completed Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns
Condition: Hepatitis B
Interventions: Biological: HepavaxGene (thiomersal free);   Biological: Engerix B
9 Completed
Has Results
Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
Condition: Influenza
Interventions: Biological: Fluarix;   Biological: Fluzone
10 Completed
Has Results
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Condition: Influenza
Interventions: Biological: GSK investigational vaccine GSK1557482A;   Biological: Fluzone®
11 Completed Immunogenicity and Safety of GSK Biologicals' FluLaval® TF
Conditions: Influenza;   Influenza Vaccines
Intervention: Biological: FluLaval® TF
12 Completed
Has Results
Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control
Condition: Influenza
Interventions: Biological: GSK Biologicals' influenza vaccine GSK1557482A;   Biological: Vaxigrip
13 Completed
Has Results
Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup
Condition: Influenza
Interventions: Biological: Cell culture derived seasonal trivalent influenza vaccine (cTIV);   Biological: Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).;   Biological: cTIV or eTIV_a;   Biological: cTIV+PV OR eTIV_a+PV
14 Completed A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population Aged 5 Through to 17 Years of Age
Condition: Influenza, Human
Interventions: Biological: bioCSL QIV;   Biological: Comparator QIV
15 Completed Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine
Condition: Hepatitis B
Intervention: Biological: Hepatitis B vaccine
16 Completed
Has Results
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children
Condition: Influenza Caused by the Novel Influenza A (H1N1) Virus
Intervention: Biological: CSL425
17 Completed
Has Results
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults
Condition: Influenza Caused by the Novel Influenza A (H1N1) Virus
Intervention: Biological: CSL425
18 Completed The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma)
Condition: Healthy
Intervention: Biological: DPT/HepatitisB/Hib vaccine
19 Completed
Has Results
Influenza Vaccine in Pregnant Women
Condition: Influenza
Interventions: Biological: Fluzone®;   Biological: Fluarix®
20 Completed Immunogenicity and Safety of DTP/HB/Hib (Bio Farma)Compared to DTP/HB Given Simultaneously With Hib(Registered)Vaccine
Condition: Healthy
Interventions: Biological: DTP/HB/Hib vaccine;   Biological: DTP/HB and Hib vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.